厄贝沙坦联合胺碘酮治疗慢性心力衰竭合并室性心律失常的临床疗效分析被引量：8

Analysis of Clinical Effect on Irbesartan- Amiodarone Combination In Treatment of Chronic Heart Failure With Ventricular Arrhythmia

下载PDF

导出

摘要目的探究厄贝沙坦联合胺碘酮治疗慢性心力衰竭合并室性心律失常的临床疗效。方法对照组慢性心力衰竭合并室性心律失常患者单纯经胺碘酮治疗,观察组经厄贝沙坦联合胺碘酮治疗。结果观察组治疗后心功能临床总有效率与心律失常临床总有效率为92.1%高于对照组;且心率、射血分数及QT离散度临床指标改善程度均优于对照组,具有统计学差异(P<0.05)。结论厄贝沙坦联合胺碘酮治疗慢性心力衰竭合并心律失常,可改善心功能与心律失常情况。 Objective To explore the clinical effect on irbesartanamiodarone combination in treatment of chronic heart failure with ventricular arrhythmia. Methods The patients in control group with chronic heart failure with ventricular arrhythmia were simply treated with amiodarone treatment, the patients in observation group were treated with irbesartan- amiodarone combination. Results The total effective rate of cardiac function and clinical arrhythmia was 92.1%. was higher than the control group. The improvement of clinical the heart rate, ejection fraction and QT dispersion degree in observation group were superior to control group significantly（P〈0.05）. Conclusion The clinical effect on irbesartanamiodarone combination in treatment of chronic heart failure with ventricular arrhythmia is the improvement of heart function and cardiac arrhythmias.

作者刘春英

机构地区辽宁省昌图县中心医院心血管科

出处《中国继续医学教育》 2015年第7期220-221,共2页 China Continuing Medical Education

关键词厄贝沙坦胺碘酮慢性心力衰竭室性心律失常 Irbesartan Amiodarone Chronic heart failure Ventricular arrhythmias

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献3

1雷寒.内科学[M].6版.北京:人民卫生出版社,2010:255-257.
2李庆洋.慢性心力衰竭的药物治疗进展及其现状[J].实用心脑肺血管病杂志,2012,20(6):941-943. 被引量：49
3管晓灵.厄贝沙坦治疗慢性心力衰竭的疗效观察[J].中国医药导报,2010,7(35):47-48. 被引量：7

二级参考文献28

1曹雅旻,胡大一,王宏宇,吴彦.我国基层医院慢性心力衰竭药物治疗现状调查[J].中华内科杂志,2006,45(11):907-909. 被引量：72
2Braunwald E.哈里森内科学[M].5版.王德炳,译.北京:人民卫生出版社,2003:1638.
3Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left - ventricular systolic function intolerant to angiotensin- converting enzyme inhibitors: The Charra-altemativeTrial [J]. Lancet, 2003, 362: 772-776.
4Cohn JN, Tognoni G. A randomized trial of the angiotensin - receptor blocker valsartan in chronic heart failur [J]. N Engl J Med, 2001, 345 : 1667 - 1675.
5Pitt B, Zannad F, Renne WJ, et 81. The effect of spironolactone on morbidity and mortality in patients with severe heart failure [ J ]. N EnglJ Med, 1999, 341 (10): 709-717.
6Pitt B, Renne WJ, Zannad F, et al. Eplerenone, a selective aldo- sterone blocker, in patients with left ventricular dysfunction after myo- cardial infarction [J]. N Engl J Med, 2003, 348 (14): 1309 - 1321.
7Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms [J]. N Engl J Med, 2011, 364 (1): 11-21.
8Poole Wilson PA, Swedberg. K, Cldand JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COM- ET) : randomised controlled trial [J]. Lancet, 2003, 362:7 -13.
9McMurray J, Pitt B, Latini R, et al. Effects of the oral direct lenin inhibitor aliskiren in patients with symptomatic heart failure [ J]. Circ Heart Fail, 2008, 1: 17-24.
10Swedborg K, Komajda M, Bohm M, et 8.1. Ivabradine and outcomes in chronic heart failure (SHIFT) : a randomised placebo - controlled study [J]. lancet, 2010, 376 (9744): 875-885.